1. Home
  2. EHI vs IPSC Comparison

EHI vs IPSC Comparison

Compare EHI & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Global High Income Fund Inc

EHI

Western Asset Global High Income Fund Inc

HOLD

Current Price

$6.16

Market Cap

193.9M

Sector

Finance

ML Signal

HOLD

Logo Century Therapeutics Inc.

IPSC

Century Therapeutics Inc.

HOLD

Current Price

$2.34

Market Cap

189.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EHI
IPSC
Founded
N/A
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
193.9M
189.7M
IPO Year
2003
2021

Fundamental Metrics

Financial Performance
Metric
EHI
IPSC
Price
$6.16
$2.34
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$3.50
AVG Volume (30 Days)
86.3K
991.4K
Earning Date
01-01-0001
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
91.30
EPS
N/A
N/A
Revenue
N/A
$109,164,000.00
Revenue This Year
N/A
$1,589.94
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1556.76
52 Week Low
$6.11
$0.34
52 Week High
$6.80
$2.97

Technical Indicators

Market Signals
Indicator
EHI
IPSC
Relative Strength Index (RSI) 21.89 51.68
Support Level N/A $0.49
Resistance Level $6.46 $2.71
Average True Range (ATR) 0.08 0.24
MACD -0.02 -0.00
Stochastic Oscillator 0.00 31.18

Price Performance

Historical Comparison
EHI
IPSC

About EHI Western Asset Global High Income Fund Inc

Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income and total return by investing in a world-wide portfolio of securities. The fund invests in various sectors such as Consumer Discretionary, Financials, Energy, Communication energy, Industrials, materials, and others.

About IPSC Century Therapeutics Inc.

Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.

Share on Social Networks: